Successful treatment of post-transplant CMV meningoencephalitis with third-party CMV virus-specific T cells: Lessons learned
Corresponding Author
Laura Alonso
Department of Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
Correspondence
Laura Alonso, Department of Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Email: [email protected]
Search for more papers by this authorFrancesc Rudilla
Histocompatibility and Immunogenetics Laboratory, Banc de Sang I Teixits, Cell Therapy Unit, Banc de Sang i Teixits, Barcelona, Spain
Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
Search for more papers by this authorRamón Gimeno
IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Search for more papers by this authorMargarita Codinach
Banc de Sang i Teixits, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
Search for more papers by this authorMargarita Blanco
Banc de Sang i Teixits, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
Search for more papers by this authorSergio Querol
Banc de Sang i Teixits, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
Search for more papers by this authorCristina Diaz de Heredia
Department of Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
Search for more papers by this authorCorresponding Author
Laura Alonso
Department of Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
Correspondence
Laura Alonso, Department of Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Email: [email protected]
Search for more papers by this authorFrancesc Rudilla
Histocompatibility and Immunogenetics Laboratory, Banc de Sang I Teixits, Cell Therapy Unit, Banc de Sang i Teixits, Barcelona, Spain
Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
Search for more papers by this authorRamón Gimeno
IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Search for more papers by this authorMargarita Codinach
Banc de Sang i Teixits, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
Search for more papers by this authorMargarita Blanco
Banc de Sang i Teixits, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
Search for more papers by this authorSergio Querol
Banc de Sang i Teixits, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
Search for more papers by this authorCristina Diaz de Heredia
Department of Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
Search for more papers by this authorAbstract
Cytomegalovirus encephalitis is a challenging life-threatening complication following hematopoietic stem cell transplantation for which medical treatment is usually ineffective or toxic. However, in recent years, adoptive T-cell therapy has been reported to provide a significant chance of cure for patients with viral infections. Herein, two cases of pediatric patients successfully treated with third-party donor-derived virus-specific T cells for CMV meningoencephalitis are reported.
REFERENCES
- 1Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20): 2427-2438.
- 2Van Rhee F, Barrett J. Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation. Cytotherapy. 2002; 4(1): 3-10.
- 3Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008; 40(1): 63-67.
- 4Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis. 2008; 40(1): 71-75.
- 5Bao L, Cowan M, Dunham K, et al. Adoptive immunotherapy with CMV specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother. 2012; 35(3): 293-298.
- 6Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013; 121(26): 5113-5123.
- 7Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010; 45(6): 979-984.
- 8Baghban A, Malinis M. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: a case report and review of the literature. J Neurol Sci. 2018; 15(388): 28-36.
- 9Fujiwara S, Muroi K, Tatara R, et al. Intrathecal administration of high-titer cytomegalovirus immunoglobulin for cytomegalovirus meningitis. Case Rep Hematol. 2014; 2014: 272458.
- 10Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010; 116: 4360-4367.
- 11Cummins NW, Deziel PJ, Abraham RS, Razonable RR. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis. 2009; 11: 20-27.
- 12Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs. 2010; 70: 965-981.
Citing Literature
